Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 Combined With Chemotherapy Induction on Sequential Immunotherapy Consolidation in LS-SCLC
NCT07091305Phase 2Recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Oct 2025
- Primary completion
- Aug 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of QL1706 in small cell lung cancer (SCLC), sponsored by Shanghai Chest Hospital. Started Oct 2025; status: recruiting.
02
Drugs
QL1706
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07091305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07091305.